Lung ground glass nodules detected at age 16 should be reviewed regularly (3 or 6 months) with management (e.g., anti-inflammatory treatment, non-surgical biopsy, or surgical resection) under the supervision of a physician, depending on the size and density of the nodule. Pulmonary ground-glass nodules (GGN) are common in young, female and non-smoking people and are categorized into pure ground-glass nodules (pGGN) and partially solid nodules. It can be seen in both invasive lung adenocarcinoma, precursor glandular lesions, and infections, alveolar hemorrhage, or interstitial fibrosis. Proper follow-up and management strategies can detect malignant lesions in time and reduce lung cancer mortality while avoiding overtreatment. ≤6 mm pGGN is recommended to be reviewed every 6 months; >6 mm pGGN is recommended to be reviewed every 3 months. If there is no significant change in the nodule, annual review of CT is still recommended. Partially solid nodules ≤8 mm are recommended to be reviewed at months 3, 6, and 12, followed by annual follow-up; >8 mm partially solid nodules are recommended to be reviewed every 3 months and treated with anti-inflammatory therapy. If the GGN disappears at 3 to 4 months of follow-up, these are considered transient GGNs and are considered benign lesions. Persistent GGNs (These are nodules that have persisted for at least 3 months and have not gotten smaller or disappeared on follow-up). Most are malignant, or precursor glandular lesions (with the potential to progress to malignancy). Persistent nodules or suspicious morphology (burr sign, lobulation, pleural depression, etc.), continuous growth, or partially solid nodules with solidity >8 mm can be further evaluated with positron emission computed tomography (PET) scanning, non-surgical biopsy, and/or surgical resection. The detection of pulmonary ground-glass nodules suggests consultation in a regular hospital.